LCAT and metabolic dysfunction-associated steatotic liver disease: Upon HFHC diet feeding, LCAT deficiency in hamsters exacerbated MASH, with increased hepatic ballooning, inflammation, and fibrosis, suggesting that LCAT plays a protective role against MASH and could be a therapeutic target for treating MASLD or MASH.